What exactly to make of PCR 'doubling' assets to $250B in an eye-blink...
Create a vendor selection project & run comparison reports
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
13 March 2018
click here to read more
Will Trout: I find it hard to believe that PCR could attempt to replicate Addepar's attempts to map and aggregate the entire investments ecosystem. I'm skeptical of Addepar's progress already
News article details
Asia-Pacific, EMEA, LATAM, North America